- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Nektar Therapeutics Shareholders Urged to Seek Compensation for Losses
Robbins LLP Investigates Allegations of Overstated Trial Results
Mar. 31, 2026 at 6:50pm
Got story updates? Submit your updates here. ›
A lawsuit alleges Nektar Therapeutics misled investors about the prospects of its alopecia drug trial, resulting in significant losses.San Diego TodayRobbins LLP, a leading shareholder rights law firm, has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. The lawsuit alleges that Nektar, a biopharmaceutical company, failed to disclose issues with the enrollment and protocol of its REZOLVE-AA clinical trial, leading to overstated prospects for the trial and the company's stock price.
Why it matters
This case highlights the importance of transparency and accurate disclosures from public companies, especially those in the highly regulated pharmaceutical industry. Investors rely on companies to provide truthful information about the status and prospects of their clinical trials, and any misleading statements can result in significant financial losses.
The details
According to the complaint, Nektar failed to disclose that enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards, which was likely to have a significant negative impact on the trial's results. When Nektar announced on December 16, 2025 that the trial had failed to reach statistical significance, the company attributed this to the inclusion of four patients who should not have been eligible to participate. This news caused Nektar's stock price to fall by 7.77%.
- The class period is from February 26, 2025 to December 15, 2025.
- On December 16, 2025, Nektar announced the failed results of the REZOLVE-AA trial.
The players
Nektar Therapeutics
A biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. Its lead product candidate is rezpegaldesleukin, a novel regulatory T cell stimulator for the treatment of alopecia areata.
Robbins LLP
A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
What they’re saying
“Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025.”
— Robbins LLP
What’s next
Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
The takeaway
This case highlights the importance of transparency and accurate disclosures from public companies, especially those in the highly regulated pharmaceutical industry. Investors rely on companies to provide truthful information about the status and prospects of their clinical trials, and any misleading statements can result in significant financial losses.
